All Stories

  1. Health-related quality of life in patients with palmoplantar pustulosis – a Swedish register study

    Article • Annals of Medicine, August 2024, Taylor & Francis

    Professor Marcus Schmitt-Egenolf

  2. Health-related quality of life in patients with generalized pustular psoriasis – a Swedish register study

    Article • Annals of Medicine, May 2024, Taylor & Francis

    Professor Marcus Schmitt-Egenolf

  3. The Influence of Socioeconomic Factors on Access to Biologics in Psoriasis

    Article • Journal of Clinical Medicine, November 2023, MDPI AG

    Professor Marcus Schmitt-Egenolf

  4. Prolonged Sick Leave Before and After Diagnosis of Generalized Pustular Psoriasis: A Swedish Population-based Register Study

    Article • Acta Dermato Venereologica, September 2023, Acta Dermato-Venereologica

    Professor Marcus Schmitt-Egenolf

  5. Patient reported experiences of Swedish patients being investigated for cancer during the Covid-19 pandemic

    Article • Supportive Care in Cancer, June 2023, Springer Science + Business Media

    Professor Marcus Schmitt-Egenolf

  6. The Disruptive Force of Real-World Evidence

    Article • Journal of Clinical Medicine, June 2023, MDPI AG

    Professor Marcus Schmitt-Egenolf

  7. Comorbidities in palmoplantar pustulosis: a Swedish population-based register study

    Article • British Journal of Dermatology, June 2023, Oxford University Press (OUP)

    Professor Marcus Schmitt-Egenolf

  8. Comorbidities in patients with generalized pustular psoriasis: a nationwide population-based register study

    Article • Journal of the American Academy of Dermatology, March 2023, Elsevier

    Professor Marcus Schmitt-Egenolf

  9. Economic Burden of Palmoplantar Pustulosis in Sweden: A Population-based Register Study

    Article • Acta Dermato Venereologica, January 2023, Acta Dermato-Venereologica

    Professor Marcus Schmitt-Egenolf

  10. The Use of IL-17 and IL-23 Inhibitors in Swedish Clinical Practice: A Register-Based Analysis

    Article • Dermatology, December 2022, Karger Publishers

    Professor Marcus Schmitt-Egenolf

  11. Economic Burden of Generalized Pustular Psoriasis in Sweden: A Population-Based Register Study

    Article • Psoriasis Targets and Therapy, May 2022, Taylor & Francis

    Professor Marcus Schmitt-Egenolf

  12. Severity of psoriasis: time to disentangle severity from symptom control

    Article • British Journal of Dermatology, April 2022, Oxford University Press (OUP)

    Professor Marcus Schmitt-Egenolf

  13. Prevalence and incidence of generalized pustular psoriasis in Sweden: a population‐based register study*

    Article • British Journal of Dermatology, April 2022, Oxford University Press (OUP)

    Professor Marcus Schmitt-Egenolf

  14. Diverse research designs are needed for population health: Lessons from Maslow

    Article • Lifestyle Medicine, January 2022, Wiley

    Professor Marcus Schmitt-Egenolf

  15. Drug Persistence of Biologic Treatments in Psoriasis: A Swedish National Population Study

    Article • Dermatology and Therapy, October 2021, Springer Science + Business Media

    Professor Marcus Schmitt-Egenolf

  16. Prevalence and incidence of palmoplantar pustulosis in Sweden: a population‐based register study*

    Article • British Journal of Dermatology, June 2021, Oxford University Press (OUP)

    Professor Marcus Schmitt-Egenolf

  17. Complete skin clearance and beyond

    Article • British Journal of Dermatology, October 2020, Oxford University Press (OUP)

    Professor Marcus Schmitt-Egenolf

  18. Paediatric infections in the first 3 years of life after maternal anti‐TNF treatment during pregnancy

    Article • Alimentary Pharmacology & Therapeutics, July 2020, Wiley

    Professor Marcus Schmitt-Egenolf

  19. Anti‐TNF treatment during pregnancy and birth outcomes: A population‐based study from Denmark, Finland, and Sweden

    Article • Pharmacoepidemiology and Drug Safety, February 2020, Wiley

    Professor Marcus Schmitt-Egenolf

  20. Health‐related quality of life in patients with melanoma – characterization of a Swedish cohort

    Article • British Journal of Dermatology, October 2019, Wiley

    Professor Marcus Schmitt-Egenolf

  21. Complete skin clearance and Psoriasis Area and Severity Index response rates in clinical practice: predictors, health‐related quality of life improvements and implications for treatment goals

    Article • British Journal of Dermatology, October 2019, Wiley

    Professor Marcus Schmitt-Egenolf

  22. What can we learn from ‘dropouts’ in clinical trials?

    Article • British Journal of Dermatology, February 2018, Wiley

    Professor Marcus Schmitt-Egenolf

  23. Sustained Psoriasis Area and Severity Index, Dermatology Life Quality Index and EuroQol-5D response of biological treatment in psoriasis: 10 years of real-world data in the Swedish National Psoriasis Register

    Article • British Journal of Dermatology, January 2018, Wiley

    Professor Marcus Schmitt-Egenolf

  24. Patient Registries for Safetyness

    Article • January 2018, Springer Science + Business Media

    Professor Marcus Schmitt-Egenolf

  25. How is disease severity associated with quality of life in psoriasis patients? Evidence from a longitudinal population-based study in Sweden

    Article • Health and Quality of Life Outcomes, July 2017, Springer Science + Business Media

    Professor Marcus Schmitt-Egenolf

  26. Severity of Psoriasis Differs Between Men and Women: A Study of the Clinical Outcome Measure Psoriasis Area and Severity Index (PASI) in 5438 Swedish Register Patients

    Article • American Journal of Clinical Dermatology, March 2017, Springer Science + Business Media

    Professor Marcus Schmitt-Egenolf

  27. Real-world outcomes in 2646 psoriasis patients: one in five has PASI ≥10 and/or DLQI ≥10 under ongoing systemic therapy

    Article • Journal of Dermatological Treatment, March 2017, Taylor & Francis

    Professor Marcus Schmitt-Egenolf

  28. Regional Differences in the Prescription of Biologics for Psoriasis in Sweden: A Register-Based Study of 4168 Patients

    Article • BioDrugs, January 2017, Springer Science + Business Media

    Professor Marcus Schmitt-Egenolf

  29. Periodontal Ehlers-Danlos Syndrome Is Caused by Mutations in C1R and C1S , which Encode Subcomponents C1r and C1s of Complement

    Article • The American Journal of Human Genetics, November 2016, Elsevier

    Professor Marcus Schmitt-Egenolf

  30. Physical activity and lifestyle improvement in the management of psoriasis

    Article • British Journal of Dermatology, September 2016, Wiley

    Professor Marcus Schmitt-Egenolf

  31. Healthcare Provider Type and Switch to Biologics in Psoriasis: Evidence from Real-World Practice

    Article • BioDrugs, February 2016, Springer Science + Business Media

    Professor Marcus Schmitt-Egenolf

  32. Evaluating equality in psoriasis healthcare: a cohort study of the impact of age on prescription of biologics

    Article • British Journal of Dermatology, February 2016, Wiley

    Professor Marcus Schmitt-Egenolf

  33. Register-Based Evaluation of Relative Effectiveness of New Therapies: Biologics Versus Conventional Agents in Treatment of Psoriasis in Sweden

    Article • BioDrugs, December 2015, Springer Science + Business Media

    Professor Marcus Schmitt-Egenolf

  34. The Relationship Between Disease Severity and Quality of Life In Patients With Moderate to Severe Psoriasis

    Article • Value in Health, November 2015, Elsevier

    Professor Marcus Schmitt-Egenolf

  35. Hair shaft structures in EDAR induced ectodermal dysplasia

    Article • BMC Medical Genetics, September 2015, Springer Science + Business Media

    Professor Marcus Schmitt-Egenolf

  36. News and Notices

    Article • British Journal of Dermatology, May 2015, Wiley

    Professor Marcus Schmitt-Egenolf

  37. Real-World Outcome Analysis of Continuously and Intermittently Treated Patients with Moderate to Severe Psoriasis after Switching to a Biologic Agent

    Article • Dermatology, January 2015, Karger Publishers

    Professor Marcus Schmitt-Egenolf

  38. Resource Use in Patients with Psoriasis After the Introduction of Biologics in Sweden

    Article • Acta Dermato Venereologica, January 2015, Acta Dermato-Venereologica

    Professor Marcus Schmitt-Egenolf

  39. Decision for biological treatment in real life is more strongly associated with the Psoriasis Area and Severity Index (PASI) than with the Dermatology Life Quality Index (DLQI)

    Article • Journal of the European Academy of Dermatology and Venereology, June 2014, Wiley

    Professor Marcus Schmitt-Egenolf

  40. EDAR-induced hypohidrotic ectodermal dysplasia: a clinical study on signs and symptoms in individuals with a heterozygous c.1072C > T mutation

    Article • BMC Medical Genetics, May 2014, Springer Science + Business Media

    Professor Marcus Schmitt-Egenolf

  41. Health-Care Delay in Malignant Melanoma: Various Pathways to Diagnosis and Treatment

    Article • Dermatology Research and Practice, January 2014, Hindawi Publishing Corporation

    Professor Marcus Schmitt-Egenolf

  42. Coping styles in decision-making among men and women diagnosed with malignant melanoma

    Article • Journal of Health Psychology, November 2013, SAGE Publications

    Professor Marcus Schmitt-Egenolf

  43. Systemic psoriasis therapy shows high between-country variation: a sign of unwarranted variation? Cross-sectional analysis of baseline data from the PSONET registries

    Article • British Journal of Dermatology, August 2013, Wiley

    Dr Ignacio Garcia-Doval, Professor Marcus Schmitt-Egenolf, prof.dr. Phyllis Spuls

  44. The Higher Proportion of Men with Psoriasis Treated with Biologics May Be Explained by More Severe Disease in Men

    Article • PLOS One, May 2013, PLOS

    Professor Marcus Schmitt-Egenolf

  45. Melbourne Decision Making Questionnaire--Swedish Version

    Article • January 2013, American Psychological Association (APA)

    Professor Marcus Schmitt-Egenolf

  46. Analysis of three outcome measures in moderate to severe psoriasis: a registry-based study of 2450 patients

    Article • British Journal of Dermatology, March 2012, Wiley

    Professor Marcus Schmitt-Egenolf

  47. Challenges for Synthesising Data in a Network of Registries for Systemic Psoriasis Therapies

    Article • Dermatology, January 2012, Karger Publishers

    Dr Ignacio Garcia-Doval, Professor Marcus Schmitt-Egenolf, prof.dr. Phyllis Spuls

  48. Switch to Biological Agent in Psoriasis Significantly Improved Clinical and Patient-Reported Outcomes in Real-World Practice

    Article • Dermatology, January 2012, Karger Publishers

    Professor Marcus Schmitt-Egenolf

  49. Malignant melanoma: gender patterns in care seeking for suspect marks

    Article • Journal of Clinical Nursing, July 2011, Wiley

    Professor Marcus Schmitt-Egenolf

  50. Patients’ decision making in seeking care for suspected malignant melanoma

    Article • Journal of Nursing and Healthcare of Chronic Illness, June 2010, Wiley

    Professor Marcus Schmitt-Egenolf

  51. National Registries of Systemic Treatment for Psoriasis and the European ‘Psonet’ Initiative

    Article • Dermatology, January 2009, Karger Publishers

    Professor Marcus Schmitt-Egenolf, prof.dr. Phyllis Spuls

  52. Switching Biologicals: Switching TNFα Antagonists in Psoriasis Treatment

    Article • Dermatology, January 2008, Karger Publishers

    Professor Marcus Schmitt-Egenolf

  53. PsoReg – The Swedish Registry for Systemic Psoriasis Treatment

    Article • Dermatology, January 2007, Karger Publishers

    Professor Marcus Schmitt-Egenolf

  54. Psoriasis Therapy in Real Life: The Need for Registries

    Article • Dermatology, December 2006, Karger Publishers

    Professor Marcus Schmitt-Egenolf

  55. EDAR mutation in autosomal dominant hypohidrotic ectodermal dysplasia in two Swedish families

    Article • BMC Medical Genetics, November 2006, Springer Science + Business Media

    Professor Marcus Schmitt-Egenolf

  56. Association scan of the novel psoriasis susceptibility region on chromosome 19: evidence for both susceptible and protective loci

    Article • Experimental Dermatology, August 2003, Wiley

    Professor Marcus Schmitt-Egenolf

  57. Interleukin-10 promoter polymorphism IL10.G and familial early onset psoriasis

    Article • British Journal of Dermatology, August 2003, Wiley

    Professor Marcus Schmitt-Egenolf

  58. Association and Linkage of Human Leukocyte Antigens with Psoriasis – Revisited

    Article • Transfusion Medicine and Hemotherapy, December 2002, Karger Publishers

    Professor Marcus Schmitt-Egenolf

  59. Comparative association analysis reveals that corneodesmosin is more closely associated with psoriasis than HLA-Cw*0602-B*5701 in German families

    Article • Tissue Antigens, May 2001, Wiley

    Professor Marcus Schmitt-Egenolf

  60. Genomewide Scan in German Families Reveals Evidence for a Novel Psoriasis-Susceptibility Locus on Chromosome 19p13

    Article • The American Journal of Human Genetics, October 2000, Elsevier

    Professor Marcus Schmitt-Egenolf

  61. PERB11 (MIC): a polymorphic MHC gene is expressed in skin and single nucleotide polymorphisms are associated with psoriasis

    Article • Clinical & Experimental Immunology, March 2000, Wiley

    Professor Marcus Schmitt-Egenolf

  62. Promoter Polymorphism at –238 of the Tumor Necrosis Factor Alpha Gene is Not Associated with Early Onset Psoriasis when Tested by the Transmission Disequilibrium Test

    Article • Journal of Investigative Dermatology, April 1999, Elsevier

    Professor Marcus Schmitt-Egenolf

  63. Immunsystem Haut

    Article • January 1999, Springer Science + Business Media

    Professor Marcus Schmitt-Egenolf

  64. Association between interleukin-1 receptor antagonist (IL-1ra) gene polymorphism and early and late-onset psoriasis

    Article • British Journal of Dermatology, January 1997, Wiley

    Professor Marcus Schmitt-Egenolf

  65. Familial Juvenile Onset Psoriasis Is Associated with the Human Leukocyte Antigen (HLA) Class I side of the Extended Haplotype Cw6-B57-DRB1*0701-DQA1*0201-DQB1*0303: A Population- And Family-Based Study

    Article • Journal of Investigative Dermatology, April 1996, Elsevier

    Professor Marcus Schmitt-Egenolf

  66. Analysis of TAP2 and HLA-DP gene polymorphism in Psoriasis

    Article • Human Immunology, August 1994, Elsevier

    Professor Marcus Schmitt-Egenolf

  67. Oligonucleotide Typing Reveals Association of Type I Psoriasis with the HLA-DRB1*0701/2, -DQA* 0201, -DQB1*0303 Extended Haplotype

    Article • Journal of Investigative Dermatology, June 1993, Elsevier

    Professor Marcus Schmitt-Egenolf

  68. Type I and Type II psoriasis Show a Similar Usage of T-Cell Receptor Variable Regions

    Article • Journal of Investigative Dermatology, December 1991, Elsevier

    Professor Marcus Schmitt-Egenolf